Abstract

BackgroundBilirubin has antioxidant properties against chronic respiratory diseases. However, previous studies are limited by acquisition of serum bilirubin level at one time point and its analysis with clinical parameters. We evaluated the association of serum bilirubin levels with various clinical outcomes of chronic obstructive pulmonary disease (COPD) in Korean Obstructive Lung Disease (KOLD) cohort.MethodsWe included 535 patients with COPD from the KOLD cohort. Serum bilirubin levels and various clinical parameters, such as lung function, 6-min walking (6 MW) distance, quality of life (QoL), and exacerbation, were evaluated annually; their association was analyzed using generalized estimating equations and the linear mixed model.ResultsAmong 535 patients, 345 (64.5%) and 190 (35.5%) were categorized into Global Initiative for Chronic Obstructive Lung Disease (GOLD) I-II and GOLD III-IV groups, respectively. 6 MW distance was positively associated with serum bilirubin levels, especially in the GOLD I-II group (estimated mean = 41.5). Among QoL indexes, the COPD assessment test score was negatively associated with serum bilirubin levels only in the GOLD I-II group (estimated mean = − 2.8). Higher serum bilirubin levels were independently associated with a higher number of acute exacerbation in the GOLD III-IV group (estimated mean = 0.45, P = 0.001). Multivariate analysis revealed that lung function and mortality were not associated with serum bilirubin levels.ConclusionsHigher serum bilirubin levels were associated with a longer 6 MW distance and better QoL, especially in the GOLD I-II group, whereas they were related to a higher risk of acute exacerbation, especially in the GOLD III-IV group. Bilirubin levels may represent various conditions in COPD.

Highlights

  • Bilirubin has antioxidant properties against chronic respiratory diseases

  • Higher serum bilirubin levels were associated with a longer 6 6-min walking distance (MW) distance and better quality of life (QoL), especially in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) I-II group, whereas they were related to a higher risk of acute exacerbation, especially in the GOLD IIIIV group

  • For comparison with the results of previous conflict results, we aimed to evaluate the association of both baseline and repeatedly measured serum bilirubin levels with various clinical outcomes of chronic obstructive pulmonary disease (COPD) in Korea, including lung function, quality of life (QoL), exercise capacity, exacerbation, and mortality

Read more

Summary

Introduction

Bilirubin has antioxidant properties against chronic respiratory diseases. Previous studies are limited by acquisition of serum bilirubin level at one time point and its analysis with clinical parameters. We evaluated the association of serum bilirubin levels with various clinical outcomes of chronic obstructive pulmonary disease (COPD) in Korean Obstructive Lung Disease (KOLD) cohort. Chronic obstructive pulmonary disease (COPD) is characterized by persistent respiratory symptoms and airflow limitation caused by significant exposure to noxious particles or gases [1]. Bilirubin is known as a potential antioxidant and possesses anti-inflammatory properties [3]. Several reports demonstrate the relationship between bilirubin level and respiratory diseases. In the United Kingdom, higher level of bilirubin was associated with a lower risk of COPD, lung cancer, and all-cause mortality [5].

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.